2-[[(2R)-3-acetyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 2-[[(2R)-3-acetyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C10H23NO7P+
• 分子量: 300.27
• InChiKey: RYCNUMLMNKHWPZ-SNVBAGLBSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  19
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PIPEMIDIC ACID DERIVATIVE AUTOTAXIN INHIBITORS
  申请人：Parrill-Baker Abby Louise

  公开号：US20120100592A1

  公开（公告）日：2012-04-26

  Novel and optimized classes of pipemidic acid derivative compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes of compounds exhibit exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.

  本发明提供了一种新型和优化的pipemidic酸衍生物类化合物，它们能够有效地抑制自体趋化素酶。这些化合物类别表现出与自体趋化素反应性，最终减小其上的反应性位点的大小，以防止溶血磷脂酰胆碱转化为溶血磷脂酸。此外，这些化合物可以被纳入人体摄入的递送形式中。因此，这些化合物为潜在地减少由于人体内天然存在的自体趋化素而导致某些癌症的产生提供了出色的方式。本发明还涵盖了使用这些化合物使自体趋化素在一定程度上失活的方法。
• NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS
  申请人：LIFE SCIENCE NUTRITION AS

  公开号：US20160024125A1

  公开（公告）日：2016-01-28

  Provided herein is technology relating to natural lipids containing non-β-oxidizable fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of natural lipids containing non-β-oxidizable fatty acids.

  本技术涉及含有非β氧化脂肪酸的天然脂类，特别是但不限于与含有非β氧化脂肪酸的天然脂类的组合物和方法相关的生产和使用。
• SULFUR-CONTAINING PHOSPHOLIPID DERIVATIVES
  申请人：MILLER Andrew David

  公开号：US20120264966A1

  公开（公告）日：2012-10-18

  The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO 2 , SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)] m PHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

  本发明提供了一种脂质化合物，其包括至少一个非极性基团和一个极性基团，其中每个或至少一个非极性基团的公式为X-Y-Z，其中X是一个烃基链，Y选择至少一个S、Se、SO2、SO和O，Z是一个可选的烃基团，极性基团的公式为-[C（O）]mPHG，其中PHG是极性头基团，m是非极性基团的数量。
• MECHANISM-BASED INACTIVATORS OF AUTOTAXIN
  申请人：Parrill-Baker Abby Louise

  公开号：US20100136650A1

  公开（公告）日：2010-06-03

  A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C 12 -C 18 phosphodiesters and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds are non-cytotoxic, and can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of producing such novel compounds are encompassed within this invention as well as methods of inactivating autotaxin to certain degrees therewith.
• Novel Diverse Lead Compound Autotaxin Inhibitors
  申请人：Parrill-Baker Abby Louise

  公开号：US20110160148A1

  公开（公告）日：2011-06-30

  Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.